The main purpose of this study is to see how effective and safe CREXONT^® is for people with Parkinson’s disease (PD) in everyday life. CREXONT is a combination of levodopa (LD) and carbidopa (CD) used to treat PD. It was approved by the Food and Drug Administration (FDA) in August 2024. Enrolling in the Miami and Boca Raton clinics.

The main goals of this study are to assess if TB006 can improve motor function (movement-related symptoms) in Parkinson's disease patients, and to determine if TB006 is safe for use in this patient population.

This Phase 3 clinical trial is open to both participants who have previously been participating in the Dimension or Surveyor studies, as well as those who have not. The study is currently enrolling patients for its open label phase to receive the investigational drug, SAGE-718

A Phase II, Multicentre, Randomised, Double-blind, Placebo-controlled Sequential Cohort Study to Evaluate the Efficacy and Safety of IPN10200 for the Treatment of Blepharospasm in Adults

This Phase 2 study is intended to help better understand the potential impact of SAGE-718 on the day-to-day functioning of participants with HD. Like the Dimension study, you may be eligible to participate in this trial if you are between 25 and 65 years of age and have genetically confirmed HD with pre-manifest to early-manifest presentation. Additionally, this study invites healthy volunteers to participate

This phase 2 study seeks to evaluate the effect of the study drug SAGE-718 on the cognition of participants with premanifest or recent HD diagnosis. You can participate if you are between 25 to 65 years of age and have been diagnosed with early HD

This research study will gather clinical information about you and your health and collect biological samples. Researchers will use this information and samples to learn more about HD and to try to find new treatments for the disease. Study participants will be individuals affected by HD or who come from an HD family who are eligible and willing to participate in Enroll-HD. The study is available for English and Spanish-speaking participants

This study aims to explore how well people with MSA tolerate the drug ONO-2808, its effectiveness, the appropriate doses that are safe, and how the drug functions in the body. If you are 30-80 years old, diagnosed with MSA-C or MSA-P, experiencing motor symptoms for less than 5 years, and can walk 10 steps back and forth, you might be eligible to join. The study lasts for 34 weeks, with some visits conducted at your home by a study nurse

A randomized, double-blind, placebo-controlled, Phase 2 study to assess the efficacy, safety, and pharmacokinetics of FNP-223 (oral formulation) to slow the disease progression of progressive supranuclear palsy (PSP)

The FOG LIGHTS (Lessening Impairments in Gait with Hybrid Therapeutic Stimulation) Study is investigating the effectiveness of a new therapy for freezing of gait in people with Parkinsons who have an implanted deep brain stimulator. The purpose of the study is to determine whether or not CereGateTherapy can reduce freezing of gait in people with Parkinsons. CereGate therapy uses the Gevia™ DBS system that you already have, to create perceptible rhythmic sensations, or "cues", that may help to reduce your freezing of gait.

Observational study of Deep Brain Stimulation patients with Abbott DBS system conducted to gather clinical data on how Abbott DBS systems are being used in routine clinical practice

This study will test a new investigational cellular therapy product called Bemdaneprocel (stem cell derived neuronal cells) for people with Parkinson’s Disease who have 2.5 hours or more of daily OFF time. Patients are randomized to either stem cell therapy or placebo. The goal is to improve long-term PD management by improving their ability to move, slowing the disease's progress, and enhancing their quality of life. It also seeks to do this with fewer side effects than current treatments.

The purpose of this research study is to determine if DBS is a safe and effective therapy for severe freezing of gait in patients with Parkinson's Disease. Freezing of gait (FOG) is a particularly debilitating motor deficit seen in a subset of patients with Parkinson's Disease (PD).

Mapping the Future of Parkinson's Disease is a national initiative that offers genetic testing for clinically relevant Parkinson's-related genes and genetic counseling at no cost for people with Parkinson's disease, in English or Spanish. You can participate from home.

The goal of this phase 2 study is to see whether the study drug might delay PD by modifying the activity of a gene involved in PD called GBA1. You may be eligible to participate if you are between the ages of 30 and 80 years old, have had between 1 and 7 years of Parkinson’s disease symptoms, are able to walk without assistance, and are taking medication for Parkinson’s disease.

This study is to investigate if adding a medication called Lenrispodun to your current Parkinson's disease (PD) treatment can help make your symptoms better. You may be eligible to participate if you areexperiencing wearing OFF symptoms or dyskinesia and currently taking carbidopa/levodopa.

The goal of this study is to investigate whether BIIB122 (study drug) may delay progression of PD. You may be eligible to participate if you are between 30 to 80 years of age and have been recently diagnosed with early-stage PD.

For patients who have had DBS surgery with the Boston Scientific Study. The main goal is to characterize real-world clinical outcomes of DBS using a retrospective review of de-identified patient records. This study is data collection only.

Vercise™ DBS Registry: For patients considering Deep Brain Stimulation – Boston Scientific Corporation’s commercially approved Boston Scientific Vercise™ System for DBS. This study will evaluate the economic value and technical performance of the Vercise™ System.

The purposes of this study are to identify persons with rapid-onset dystonia-parkinsonism (RDP), alternating hemiplegia of childhood (AHC), or other diseases caused by mutations of the ATP1A3 gene, document prevalence of the disease, and map its natural history. This study, which is a continuation of an earlier study begun by Dr. Allison Brashear, aims to more clearly identify the characteristics associated with ATP1A3 disease and to explore whether mutations in the gene are associated with atypical dystonias, Parkinson's disease, and other movement disorders. The study involves in-person or remote (telemedicine) neurological assessments and blood samples for genetic analysis.